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ABBREVIATIONS 
MI   Myocardial Infarction 
NTI   Non Thyroidal illness 
SES   Sick Euthyroid Syndrome 
AMI   Acute Myocardial Infarction 
AWMI  Anterior Wall Myocardial Infarction 
IWMI  Inferior Wall Myocardial Infarction 
LVEF  Left Ventricular Ejection Fraction 
T3   Tri iodo thyronine 
T4    Thyroxine 
TSH   Thyroid Stimulating Hormone 
rT3   Reverse Tri iodo thyronine 
TRH   Thyrotropin Releasing Hormone 
TBPA   Thyroxine Binding Prealbumin 
NEFA   Non Esterified Fatty Acid 
TBG    Thyroxin Binding Globulin 
TNF    Tumor Necrosis Factor 
EF   Ejection Fraction 
CABG  Coronary Artery Bypass Surgery 
GGH   Government General Hospital 
ECG   Electrocardiography 
ECHO  Echocardiography 
HT   Hypertension 
DM   Diabetes Mellitus 
3,3’,5’ -T3   3,3',5'-triiodothyronine (reverse T3) 
 3,5,3’, -T3   3,5,3'-triiodothyronine (T3) 
JVP   Jugular Venous Pressure 
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INTRODUCTION 
Sick euthyroid syndrome can be described as abnormal findings on thyroid 
function tests that occur in the setting of a nonthyroidal illness (NTI) without 
preexisting hypothalamic-pituitary and or thyroid gland dysfunction.11-13 
A decreased level of serum total triiodothyronine (T3) is the most common thyroid 
function abnormality in patients with acute illness[14] and can be detected within 2 
hours after the onset of severe physical stress.[15] As the severity of illness 
progresses, there is gradual development of a more complex syndrome associated 
with low levels of T3 and thyroxine (T4).[16,17]Levels of thyrotropin (TSH) remain 
unchanged or slightly reduced. The conversion of the pro-hormone (Thyroxine, 
T4) to the active form is reduced due to decreased 5’-deiodinase activity 
peripherally and production of reverse T3 (rT3), the inactive metabolite, is 
increased. 
These thyroid hormone changes may be mediated in part by cytokines or other 
inflammatory mediators, acting at the level of the hypothalamus and pituitary, the 
thyroid gland, and the hepatic deiodinase system, as well as on binding of 
thyroxine to thyroid binding globulin.(TBG) 
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It remains unresolved whether the hormone responses in the sick euthyroid 
syndrome represent part of an adaptive response, which lowers tissue energy 
requirements in the face of systemic illness, or a maladaptive response, which 
induces damaging tissue hypothyroidism. 
Consequently, the use of thyroid hormone therapy in the sick euthyroid syndrome 
is controversial. 
Recovery from the underlying illness is accompanied by disappearance of the 
thyroid abnormalities. 
Altered thyroid hormone levels have been reported in starvation,[10] acute and 
chronic medical illnesses,[29-31] bone marrow transplantation,[8] surgery,[9] 
trauma,[22],myocardial infarction 4 and, in fact, can be seen in any severe systemic 
illness.[28]  
The more profound the changes in hormone pattern, the poorer the prognosis.[18,19]. 
Sick euthyroid syndrome has also been demonstrated in acute myocardial 
infarction and a correlation between the severity of the cardiac damage and the 
degree of the change in thyroid hormones was postulated.4 
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The aim of the present investigation is to study the occurrence of  Sick Euthyroid 
syndrome in patients with ST elevation myocardial infarction  and to evaluate 
whether the presence of sick euthyroid syndrome in these patients have any 
prognostic significance in determining severity of AMI. 
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Background 
In severe illness of any cause, depression of the thyroid hormone system may 
occur in otherwise euthyroid patients. In this condition, called the sick euthyroid 
syndrome, the normal feed-back control of the thyroid homeostasis is changed.11-13 
Based upon the conviction that patients with systemic illnesses are euthyroid, 
Wartofsky and Bunnan[14] in 1982 used the term sick euthyroid syndrome to 
describe the spectrum of thyroid abnormalities associated with nonthyroidal 
illness.  
  Relationship between serum thyroid hormone concentrations and severity of 
    Non thyroidal illness (NTI) 
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In critical illness, correlation between the severity of the illness and the degree of 
the change in thyroid hormones was described. 
Recovery from the underlying illness is accompanied by disappearance of the 
thyroid abnormalities. 
Pituitary-Thyroidal Axis  
Secretion of thyroid hormones from the thyroid gland is controlled by pituitary 
thyrotropin/thyroid-stimulating hormone (TSH) release, which is in turn controlled 
by hypothalamic thyrotropin-releasing hormone (TRH). Thyroxine and T3, the 
main circulating thyroid hormones, exert feedback inhibition at the pituitary and 
hypothalamic level.[23]  
Thyroxine is nearly completely produced in the thyroid gland, and once secreted in 
the circulation, is peripherally deiodinated to T3 in the liver, kidney and skeletal 
muscle .[23] Two peripheral enzymes deiodinate T4:( 1) 5'-monodeiodinase converts 
T4 to its active metabolite, 3,5,3'-T3[23,77]; whereas( 2)5-monodeiodinase converts 
T4 to reverse T3 (3,3',5'-T3), a biologically inactive metabolite. In addition to 
peripheral deiodination, there is local deiodination of T4 to T3 in the pituitary 
gland.[16,78]  
More than 99% of T4 and T3 is bound to thyroxine-binding globulin (TBG), T4-
binding prealbumin (TBPA, also termed transthyretin), and albumin. Only free, 
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unbound T3 (approximately 0.2% of the total T3) is metabolically active. 
Triiodothyronine enters the cell nucleus, binds to its nuclear receptor, and regulates 
transcription of thyroid hormone-responsive genes, resulting in the physiologic 
changes associated with thyroid hormone action.[79] 
Pathophysiology 
Proposed mechanisms explaining abnormalities in thyroid hormone levels 
Inhibition of thyroid hormone binding to thyroid-binding proteins and tissues 
Some authors propose that serum thyroid hormone abnormalities are due to 
inhibition of thyroid hormone binding to proteins, thus preventing tests from 
appropriately reflecting free hormone levels. This binding inhibitor can be present 
both in the serum and in body tissues and might inhibit uptake of thyroid hormones 
by cells or prevent binding to nuclear T3 receptors, thus inhibiting the action of the 
hormone. This inhibitor is associated with the nonesterified fatty acid (NEFA) 
fraction in the serum. [31,89,51] 
Thyroxine-binding globulin decrease and desialation 
Thyroxine binding globulin (TBG) is a member of the serine protease inhibitors. 
Diminished T4 in NTI has been proposed to be due to low TBG caused by protease 
cleavage at inflammatory sites in acute inflammatory conditions. One other 
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hypothesis for the cause of disproportionately low serum T4 concentrations in 
patients with NTI is the presence of abnormal serum binding due to desialation of 
TBG. 14,29,51 
Cytokines  
Cytokines are thought to play a role in NTI—particularly interleukin (IL)-1, IL-6, 
tumor necrosis factor (TNF)-alpha, and interferon-beta. Cytokines are thought to 
affect the hypothalamus, the pituitary, or other tissues, inhibiting production of 
TSH, thyroid-releasing hormone (TRH), thyroglobulin, T3, and thyroid-binding 
globulins. Cytokines are also thought to decrease the activity of type I deiodinase 
and to decrease the binding capacity of T3 nuclear receptors. 36,38 
Deiodination 
Peripheral deiodination of T4 to T3 is impaired, largely secondary to decreased 
activity of type I deiodinase enzyme, which deiodinates T4 to T3. Diminished 
enzyme activity accounts for decreased deiodination of T4 to T3.23,24 
An alternative explanation is that reduced tissue uptake of T4 secondary to 
deficiency of cytosolic cofactors (eg, nicotinamide adenine dinucleotide phosphate 
[NADPH], glutathione) results in decreased substrate for type I deiodinase 
enzyme. Type I deiodinase is a selenoprotein; because selenium deficiency is 
common in critically ill patients, some propose that selenium deficiency may 
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contribute to type I deiodinase malfunction. Cytokines (eg, IL-1 beta, TNF-alpha, 
interferon-gamma) decrease type I deiodinase messenger RNA (mRNA) in vitro. 
Type I deiodinase does not exist in the pituitary, where T3 levels are within the 
reference range, because of enhanced local deiodination. This indicates that an 
enhancement of intrapituitary T4 to T3 conversion exists due to pituitary-specific 
and brain-specific type II deiodinase. 
Inhibition of thyroid-releasing hormone and thyroid-stimulating hormone 
secretion  
Cytokines, cortisol, and leptin, as well as changes in brain thyroid hormone 
metabolism, affect inhibition and secretion of TRH and TSH. 8,81,34 
Inhibition of plasma membrane transport of iodothyronines 
Serum factors, such as bilirubin, NEFA, furanoic acid, hippuric acid, and indoxyl 
sulphate, which are present in various NTIs, have been shown to inhibit transport 
of thyroid hormones. 
The effects of nonthyroidal illness 
Triiodothyronine and reverse triiodothyronine 
In healthy people, 20% of T3 production comes from thyroidal secretion and 80% 
from peripheral deiodination from T4. In NTI, the thyroidal production of T3 is 
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normal, but the peripheral production of T3 is decreased. The fractional rate of 
transport of T3 to tissues is unaltered. Production of T3 is decreased, but its 
clearance is unchanged. Production of rT3 is unchanged, while its clearance is 
diminished. 
Reduced  5'-deiodinase tissue activity, results in decreased T3 production from T48 
and reduced breakdown of rT3. The decreased production of T3 during early and 
late starvation has been explained as either a diminished activity of the enzyme 
(deiodinase) itself or a deficiency of cytosolic cofactors, such as NADPH or 
glutathione. Specific deiodinative enzymes, 3 of which have been identified, affect 
deiodination of iodothyronines. Type I deiodinase is present in the liver, kidney, 
and thyroid and affects both 5 and 5' deiodination of T3. Type II deiodinase is 
present in the brain, pituitary, and brown adipose tissue and is active only in 5' 
deiodination. Type III deiodinase is found particularly in the brain, skin, and 
placenta, and it deiodinates  iodothyronines at the 5 locations. 80,89,90 
type I deiodinase is a selenoprotein and selenium deficiency is common in 
critically ill patients, selenium deficiency also may contribute to its malfunction. 
Cytokines, such as IL-1 beta, TNF-alpha, and interferon-gamma, decrease type I 
deiodinase mRNA. 59 
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Free triiodothyronine 
Most studies have found free T3 hormones to be depressed. 
Thyroxine 
The decrease in the T4 binding of TBG has been used as an explanation for the low 
plasma T4 concentration in patients with NTI. The existence of a binding inhibitor 
could explain the observed alterations in T4 and free T4 fraction. TBG levels 
usually are within the reference range in patients with NTI and are somewhat lower 
in critically ill patients with low serum T4. Low TBG levels can be explained, 
according to some proposals, by rapid protease cleavage at inflammatory sites, 
particularly in acute inflammatory states (in which the decrease in TBG is too rapid 
to be accounted for by inhibition of synthesis). 
In patients with NTI, serum T4 concentration has been demonstrated to be low 
because much of the circulating TBG in these patients is desialated. In NTI, the 
fractional rate of T4 transport from serum to tissues is reduced to 50% of the 
reference range value. This decrement in fractional rate of T4 transport is not 
related to the serum levels of total or free T4. Because in illness the reduction in 
the fractional rate of T4 transport from serum to tissues cannot be attributed to 
alterations in serum T4 binding, consider other causes such as an impairment of 
transport into tissues. In nonuremic critical illness, it has been demonstrated that 
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elevated bilirubin or elevated NEFA and low albumin concentration may be at 
least partially responsible for the T4 transport inhibition in T3-producing tissues 
(eg, the liver). 
A correlation exists between the probability of death and the levels of total T4. 
When serum T4 levels drop below 4 mcg/dL, the probability of death is about 
50%; with serum T4 levels below 2 mcg/dL, the probability of death reaches 
80%.(40) 
Free thyroxine 
No consensus exists as to whether free T4 levels are within the reference range, 
low, or high. Free T4 is believed to represent the hormone available to tissues. 
Measurement of total serum T4 has only limited value because nearly all (99.97%) 
of the circulating T4 is bound to TBG, T4-binding prealbumin (TBPA), and 
albumin. The rest of the circulating T4 (0.2-0.03%) is free T4. The circulating 
concentration of these binding proteins is understood to affect the total T4 
concentration without necessarily changing the amount of free T4. Usually, TBG 
levels are within the reference range in patients with NTI and somewhat lower in 
critically ill patients with low serum T4. Decreased concentrations of one or more 
of the binding proteins would explain low levels of total T4 but does not explain a 
significant increase in free T4 fraction, which some patients with NTI exhibit. 
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Various explanations for the existence of inhibitors of T4 binding have been 
reported. Although low levels of TBPA and albumin may occur in patients with 
NTI, even complete inhibition of T4 binding to these proteins has been 
demonstrated to produce only about a 30% increase in free T4 fraction. Because 
free T4 fraction is increased above this level in many patients, other factors must 
be present. The observations of reduced total T4 and free T4 have been explained 
alternatively as either a fall in TBG levels or an inhibition of thyroid hormone 
binding to TBG. 
 Some studies have shown a decrease in the T4 binding of TBG, which has been 
used as an explanation for the low plasma T4 concentration and, perhaps, the high 
free T4 fractions, in patients with NTI. Other studies postulate the existence of a 
binding inhibitor that could explain the observed alterations in free T4 fraction. 
The inhibitor also has been demonstrated to interfere with the binding of 
iodothyronines to solid matrices, thus interfering with the T3 resin uptake and 
explaining the low FTI found in patients with NTI. The inhibitor appears to be 
extractable with ether and was associated with the NEFA fraction in the serum. 
Furthermore, the extracted inhibitor from sera of patients with NTI reduced 
conversion of T4 to T3 in rat liver homogenates. The inhibitor could be extracted 
from extra thyroidal tissues as well. 
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The addition of NEFA to normal serum is able to raise the free T4 fraction only if 
total NEFA concentration is higher than 3 millimoles in normal serum, 
representing a NEFA-to-albumin molar ratio greater than 5:1. Because this high 
NEFA-to-albumin ratio is not reached even in severely ill patients, NEFA is 
unlikely to influence the circulating free T4 concentration in vivo. Inhibitors of 
binding were also observed during equilibrium dialysis assay in patients treated 
with heparin. This is due to an in vitro artifact that is not present in vivo. 
Cytokines also can elevate free T4. When TNF-alpha was infused, it was observed 
that free T4 could elevate transiently in association with a significant rise in free 
fatty acids. However, other studies question the role of NEFA inhibition or 
whether any thyroid hormone–binding inhibitor exists at all. 
Thyroid hormone receptor expression and DNA binding 
In experimental mouse liver models, infection decreased thyroid hormone receptor 
(TR) expression as well as retinoid X receptor (RXR)–TR DNA binding.  
Thyroid-stimulating hormone and thyroid-releasing hormone 
Serum TSH is measured with immunometric assays. Serum TSH in NTI typically 
is within the reference range or reduced. Serum TSH may be markedly low, 
although it usually not less than 0.05 µIU/ml. These low TSH levels are often 
observed without significant decrease in T4. 
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That TSH is not elevated in the presence of low T4 indicates that the patients are 
not hypothyroid. Diminished release of TRH also is thought perhaps to result in 
low TSH and, thus, low output of thyroid hormones by the thyroid. Low TRH 
mRNA in hypothalamic paraventricular nuclei also has been demonstrated. 8,81,34 
Diagnosis of Thyroid Disease in Euthyroid Sick Syndrome 
Hypothyroidism 
Primary hypothyroidism 
Serum level of TSH >30 µU/mL is rarely seen in euthyroid sick syndrome and 
strongly suggests the diagnosis of primary hypothyroidism. Levels of TSH above 
20 µU/mL are found in <3% of patients with nonthyroidal illness 49 
Secondary hypothyroidism 
Differentiation between secondary hypothyroidism (pituitary or hypothalamic) and 
euthyroid sick syndrome may be difficult. Both conditions present with decreased 
levels of total T4, T3, and TSH. 
Additional tests, including obtaining basal and/or stimulated cortisol, serum 
gonadotropin, and prolactin levels may be of help in such cases. If the serum 
cortisol level is normal or elevated, as would be expected in stressful situations, 
euthyroid sick syndrome is probably the cause, rather than pituitary dysfunction.  
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If serum cortisol and gonadotropin levels are low, pituitary dysfunction should be 
suspected, and treatment with corticosteroids and thyroid hormone 
supplementation is indicated. 
Hyperthyroidism 
Hyperthyroid patients who are chronically ill or malnourished may have 
hypoproteinemia and low levels of TBG that lower their T4 and T3 levels. In such 
patients, an elevated free-T4 level and a low or undetectable TSH level will 
confirm the diagnosis of hyperthyroidism. 
 A previous history of thyroid illness, a history of external radiation, or the 
presence of goiter and/or a midline neck scar may indicate a primary thyroid 
condition. 
As mentioned before, certain pharmacologic agents may alter the serum 
concentration of thyroid hormones and should be taken into account in the 
evaluation of patients with nonthyroidal illness. The concentrations of total T3, 
free-T4, and TSH are reduced in patients treated with dopamine or 
corticosteroids,[81,45] due to suppression of pituitary TSH release[62] and/or 
inhibition of conversion of T4 to T3.[63] Levels of total and free-T4 may be increased 
in patients treated with amiodarone[64] or iodinated radiocontrast agents.[15,65] 
Intravenous or subcutaneous heparin therapy may result in increased free-T4 
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levels,[66] due to in vitro interference with the laboratory assay; however, most such 
patients remain clinically euthyroid and have normal total T4 and TSH levels. 
As a general rule, it is not prudent to rely solely on a single thyroid test in the 
evaluation of thyroid function of patients with critical illness. In such patients, a 
careful assessment of multiple tests may be needed to distinguish patients with 
euthyroid sick syndrome.[14] In many instances, it is reasonable to delay the final 
diagnosis for several days to weeks, or after recovery from the acute illness, to 
determine the correct thyroid status. 
Treatment 
With recovery from underlying illness, the spectrum of thyroid abnormalities 
observed in patients with euthyroid sick syndrome rapidly disappears. In critically 
ill patients, however, the presence of reduced T3 and T4 concentrations is 
associated with increased severity of illness and mortality rate.[8,40] The mortality 
rate in patients admitted to an intensive care unit is directly correlated with serum 
T4 concentration.[40]  
Because of the increased incidence of mortality observed in patients with severe 
illness and low T4 values, several interventional trials have examined the effect of 
thyroid hormone supplementation in patients with nonthyroidal illness.  
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The administration of T4 (levothyroxine) to critically ill adults has failed to 
demonstrate a reduction in the mortality rate.[41] Administration of T4 to neonates 
with respiratory distress syndrome resulted in no differences in mortality rate or 
number of days on a ventilator; similarly, T4 supplementation to preterm neonates 
showed no differences in neurodevelopment or weight.[67] The lack of beneficial 
effect with T4 treatment may be due to the inability of these patients to convert 
administered T4 to metabolically active T3. 
Several controlled studies in which T3 was administered to adult and pediatric 
patients have provided equivocal results. There are few randomized controlled 
studies reporting the benefits of T3 replacement.[68,69] In patients undergoing 
coronary bypass procedures, T3 administration improved cardiac output and 
decreased systemic vascular resistance.[68,69] In a different study, the administration 
of T3 at release of cross-clamp after myocardial revascularization resulted in 
improvement in cardiac indexes and decreased inotropic requirements, 
postoperative ischemia, mortality rate, and length of hospital stay.[70] Other 
investigators have examined the effect of T3 administration on pulmonary function 
in sepsis. These studies showed improvement in respiratory drive, pulmonary 
histologic integrity, and surfactant availability.[71] 
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In contrast, other studies have shown little or no benefit from short-term 
administration of T3. In a large, prospective, randomized, double-blind, placebo-
controlled trial, T3 was administered to 211 adults who underwent myocardial 
revascularization or valve replacement; no benefit could be demonstrated in 
inotropic requirements or need for mechanical support. Adverse events were the 
same, despite T3 administration. Similar studies of T3 administration to the same 
spectrum of patients also failed to demonstrate differences in clinical outcome.[72,73] 
 In the presence of these conflicting results, we do not recommend routine 
administration of thyroid hormones to patients with euthyroid sick syndrome. Even 
though no harm has been reported with the administration of T3 to critically ill 
patients, evidence does not support the use of thyroid hormone supplements to 
correct thyroid hormone abnormalities. 
 In critically ill patients with documented hypothyroidism, thyroid hormone 
administration is indicated. If therapy is to be given, it cannot be with T4 alone, 
because this may fail to promptly increase T3 levels (due to impaired T4-to-T3 
conversion). In patients with a variety of underlying illnesses admitted to a medical 
intensive care unit, intravenous T4 sufficient to raise the total T4 and free T4 to 
normal levels failed to increase T3 concentrations, while reverse-T3 levels did rise 
with treatment.[41]  
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Therefore, to restore T4 and T3 concentrations to normal during critical illness, 
patients should be treated with a combination of T4 and T3. The recommended 
replacement dose of T3 is 50 mg/day, given in divided doses. During treatment, 
frequent monitoring (every 48 hours) of levels of total and free T4 and T3 has been 
recommended,[32] and dosages should be adjusted to achieve a low-normal serum 
T3 level. 
Euthyroid sick syndrome and myocardial infarction 
In severe illnesses of non thyroidal origin (11–12), including myocardial infarction 
(1,76) and chronic heart failure (93), down regulation of the thyroid hormone system 
may occur.  
Thyroid hormones have substantial effects on the cardiovascular system (18,94,95,96). 
The active hormone increases heart rate, contractility, cardiac output, and 
consumption of oxygen and nutrients, mimicking the effects of catecholamines. 
However, it also decreases systemic vascular resistance and improves diastolic 
relaxation, leading to a more efficient use of energy and nutrients. 
Whether the euthyroid sick syndrome constitutes an adaptive metabolic response to 
conserve energy in cardiac disease, or whether it aggravates a patient’s condition, 
is a matter of debate. 
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Killip class and myocardial infarction 
The Killip classification is a system used in individuals with an acute myocardial 
infarction (heart attack), in order to risk stratify them. Individuals with a low Killip 
class are less likely to die within the first 30 days after their myocardial infarction 
than individuals with a high Killip class.[2] 
Killip class I includes individuals with no clinical signs of heart failure 
Killip class II includes individuals with rales in the lungs, an S3 , and elevated JVP.  
Killip class III describes individuals with frank acute pulmonary edema. 
Killip class IV describes individuals in cardiogenic shock or hypotension 
(measured as systolic blood pressure lower than 90 mmHg), and evidence of 
peripheral vasoconstriction (oliguria, cyanosis or sweating). 
 In Killip class I:  mortality rate was found to be at 6%, Killip class II:  mortality 
rate was found to be at 17%, Killip class III:  mortality rate was found to be at 38% 
and Killip class IV: Mortality rate was found to be at 81%. 
Ejection Fraction and Myocardial infarction  
 After acute myocardial infarction presence of low left ventricular ejection fraction 
are strongly associated with morbidity and mortality. 7  
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AIMS & OBJECTIVES 
1. To find out the occurrence of sick euthyroid syndrome in acute ST elevation 
myocardial infarction patients admitted to the coronary care unit at the Govt 
General Hospital Chennai. 
 
2. To find out the prognostic significance of sick euthyroid syndrome positivity in 
acute ST elevation myocardial infarction patients admitted to the coronary care 
unit at the Govt General Hospital Chennai. 
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MATERIALS & METHODS 
SETTING 
This study was conducted in the coronary care unit, GGH, Chennai in 
collaboration of institute of internal medicine, institute of Cardiology and institute 
of biochemistry. It was a prospective study done during the period from jan 2009 –
oct 2009 .50 patients with history, clinical features suggestive of ST elevation 
myocardial infarction were selected irrespective of age and sex. 
ETHICAL APPROVAL  
 Obtained  
STUDY DURATION 
This study was conducted for a period of eight months from 1st January 2009 to 
October 30, 2009. 
STUDY DESIGN 
  To find out the occurrence of sick euthyroid syndrome in acute ST elevation 
myocardial infarction patients and  prognostic significance of sick euthyroid 
syndrome positivity in acute ST elevation myocardial infarction patients ;  a single 
centre prospective cohort study.  
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INCLUSION CRITERIA 
1.  Acute ST elevation myocardial infarction patients admitted to the coronary 
care unit. 
EXCLUSION CRITERIA 
1. Patients with past or present history of thyroid dysfunction. 
2. Patients taking drugs that will affect thyroid function. 
3. Patients with chronic renal failure. 
4. Patients with decompensated liver disease. 
5. Patients with thyroid function test suggestive of primary Hypothyroidism and 
Hyperthyroidism. 
LABORATORY METHODS  
All patients underwent CBC, Blood sugar, Serum Na, Urea, Creatinine, LFT, 
Fasting lipid profile, Thyroid function tests, ECG and ECHO. The serum of 
patients was analyzed for thyroid function tests at day 1 (totalT3, total T4, TSH) 
and in sick euthyroid positive patients repeat thyroid function tests done at day 7 to 
confirm the reversal of hormone status.  
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The thyroid function test was done by ELISA method. All samples were obtained 
before reperfusion therapy. Echocardiography was done during hospital stay. 
METHODS 
STUDY POPULATION   
A total of 65 patients were enrolled for the study from the patients admitted to 
coronary care unit Govt General Hospital from the period 1st January 2009 to 
October 31st 2009. 
15 patients were excluded as per exclusion criteria. The remaining 50 patients, who 
satisfied all the inclusion  criteria were selected for the study and followed for one 
week. Written consent was obtained from all patients participating in the study.    
All patients were subjected to a detailed clinical history and thorough physical 
examination as per proforma. The complicated cases identified by KILLIP 
classification criteria and ejection fraction. 
The serum of patients was analyzed for thyroid function tests at day 1 
(T3,T4,TSH)and in sick euthyroid positive patients repeat thyroid function tests 
done at day 7 to confirm the reversal of hormone status. 
Day 1samples were obtained before reperfusion therapy. 
Echocardiography was done during hospital stay. 
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All patients underwent CBC, Blood sugar, Serum Na, Urea, Creatinine, LFT, 
Fasting lipid profile, Thyroid function tests, ECG, ECHO. 
FINANCIAL SUPPORT: nil. 
CONFLICT OF INTEREST: nil. 
STATISTICAL ANALYSIS 
      Data analysis was done with use of SPSS, version 10. Descriptive statistics 
were used to calculate the frequency, mean, median, and standard deviation. To 
examine the linear trend of the proportions, trend chi-square was used and to find 
the test of association chi-square was computed. 
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RESULTS 
OCCURRENCE OF SICK EUTHYROID AMONG MI PATIENTS 
POSITIVE 21
NEGATIVE 29
 
In our study 42% of ST elevation MI patients had sick euthyroid syndrome.so 
occurrence of sick euthyroid syndrome in our patients 42%.p value was 0.258.  
SEX DISTRIBUTION AMONG MI PATIENTS 
MALE  40
FEMALE 10
 
In our study male to female ratio 4:1 
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SEX DISTRIBUTION & SICK EUTHYROID SYNDROME  
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    SEX DISTRIBUTION AND SICK EUTHYROID SYNDROME(SES) 
 SES +ve PERCENTAGE SES-ve PERCENTAGE TOTAL 
FEMALE 6 60% 4 40% 10 
MALE 15 37.5% 25 62.5% 40 
 
In our study occurrence of sick euthyroid syndrome was 60% among females and 
37.5% among males. This observation was statistically insignificant with the p 
value of 0.50. 
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AGE GROUP & SICK EUTHYROID SYNDROME 
AGE GROUP
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 AGE DISTRIBUTION & SICK EUTHYROID  SYNDROME 
AGE GROUP SES+ve PERCENTAGE SES-ve PERCENTAGE TOTAL 
20 to 39 years 0 - 2 100% 2 
40 to 59 years 11 37% 19 63% 30 
>60 years 10 55% 8 45% 18 
 21  29  50 
 
In our study in the age group of 20 to 39, no one had sick euthyroid syndrome. In 
the age group of 40 to 59, 37% had sick euthyroid syndrome. In the age group of 
>60, 55% of patients had sick euthyroid syndrome. p value was 0.206 that 
statistically insignificant. 
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TYPE OF MYOCARDIAL INFARCTION AMONG PATIENTS  
OTHERS 3
IWMI 19
AWMI 28
 
In our study total fifty acute ST elevation MI patients  
           AWMI patients 28(56%) 
  IWMI patients 19(38 %) 
  Others                3(6%) 
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OCCURRENCE OF SICK EUTHYROID IN DIFFERENT TYPES OF MI 
DIAGNOSIS
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C
ou
nt
30
20
10
0
SICK EYTHYROID SYN
POSITIVE
NEGATIVE
3
8
10
11
18
 
 TYPES OF MI AND SICK EUTHYROID SYNDROME  
 SES +ve PERCENTAGE SES-ve PERCENTAGE TOTAL
AWMI 10 36% 18 64% 28 
IWMI 8 42% 11 58% 19 
OTHERS 3 100% - - 3 
 
In our study occurrence of sick euthyroid syndrome in AWMI patients was 36%, in 
IWMI patients was 42% and in others 100% .p value was 0.20 that statistically 
insignificant. 
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OCCURRENCE OF SICK EUTHYROID IN VARIOUS CLASS OF KILLIP 
KILLIP CLASS
4321
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 KILLIP CLASS AND SICK EUTHYROID SYNDROME 
 SES +ve PERCENTAGE SES-ve PEERCENAGE TOTAL 
KILLIP 1 7 25% 21 75% 28 
KILLIP 2 10 59% 7 41% 17 
KILLIP 3 2 67% 1 33% 3 
KILLIP 4 2 100% - - 2 
 21  29  50 
 
In our study patients who presented with KILLIP 1 the sick euthyroid syndrome 
occurrence was 25%, in KILLIP 2  was 59%, in KILLIP 3 was 67% and KILLIP 4  
was 100%.P value was 0.05* that statistically significant between the KILLIP 1 
and KILLIP 2. 
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SICK EUTHYROID SYNDROME AND KILLIP CLASS 
 KILLIP CLASS 
 I II III IV TOTAL
 No % No % No % No %  
SES+ve 7 33.3% 10 47.6% 2 9.5% 2 9.5% 21 
SES-ve 21 72.4% 7 24.1% 1 3.4% 0  29 
TOTAL 28 56% 17 34% 3 6% 2 4% 50 
 
In our study 47.6% of sick euthyroid  positive  patients are  in KILLIP 2 .But sick 
euthyroid  negative patients only 24.1%  in KILLIP 2. This observation was 
statistically significant with p value of 0.032** . Sick euthyroid negative patients 
are mostly in KILLIP 1.(72.4%) 
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KILLIP CLASS AND MEAN LEVEL OF HORMONES 
 MeanT3level ng/ml Mean T4 level ng/ml Mean TSH level 
 ng/ml Std devi ng/ml Std devi Mic unit/ml Std devi 
KILLIP 1 0.91(28) .43302 90(28) 17.5778 1.71(28) 1.19447 
KILLIP 2 0.63(17) .31924 70(17) 20.8148 1.46(17) 0.70425 
KILLIP 3 0.46(3) .08145 60(3) 12.490 1.43(3) 0.75719 
KILLIP 4 0.39(2) .04243 52(2) 28.282 .60(2) 0.42426 
p  value    0.031**  0.001**      0.474 
 
In our study between the groups of KILLIP class decrease of Mean T3 level, Mean 
T4 level was statistically significant. But decrease of Mean TSH level was 
statistically insignificant. 
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OCCURRENCE OF SICK EUTHYROID SYNDROME 
 IN LVEF <50 AND LVEF >50 
EJECTION FRACTION
LVEF >50LVEF <50
C
ou
nt
20
18
16
14
12
10
8
6
4
SICK EUTHYROID SYN
NEG
POS
6
15
19
10
 
 LVEF AND SICK EUTHYROID SYNDROME 
 SES+ve PERCENTAGE SES-ve PERCENTAGE TOTAL 
LVEF<50 15 60% 10 40% 25 
LVEF>50 6 24% 19 76% 25 
 21  29  50 
 
In our study patients who presented with LVEF<50 the occurrence of sick 
euthyroid syndrome was 60% and patients who presented with LVEF>50 was 
24%.    p value was 0.01** that statistically significant. 
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SICK EUTHYROID SYNDROME AND LVEF  
EJECTION FRACTION  
LVEF<50 LVEF>50 
 PATIENTS PERCENTAGE PATIENTS PERCENTAGE
SES+ve 15 71.4% 6 28.6% 
SES-ve 10 34.5% 19 65.5% 
TOTAL 25 50% 25 50% 
 
In our study 71.4% of sick euthyroid positive patients are in LVEF<50 But 34.5% 
of sick euthyroid negative patients only in this group. This observation was 
statistically significant with p value of 0.010**   
LVEF AND MEAN LEVEL OF HORMONES 
 MeanT3level ng/ml Mean T4 level ng/ml Mean TSH level 
 ng/ml(n) Std devi ng/ml(n) Std devi ng/ml(n) Std devi 
LVEF<50 0.62(25) 0.3323 68(25) 20.3046 1.16(25) 0.6305 
LVEF>50 0.91 0.4280 92(25) 16.5582 1.97(25) 1.1670 
P value 0.009** 0.000** 0.004** 
 
In our study the decrease of MeanT3level, Mean T4 level and Mean TSH level 
between the two groups of patients who presented with LVEF <50 and LVEF>50 
was observed. This observation was statistically significant. 
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ICU STAY AND SICK EUTHYROID SYNDROME 
ICU STAY DAYS
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ICU STAY AND SICK EUTHYROID SYNDROME 
 
Sick Euthyroid 
Syndrome Mean days no Std. Deviation 
NEG 3.4483 29 1.12078 
POS 4.3889 18 1.09216 
Total 3.8085 47 1.19124 
 
In our study in sick euthyroid positive patients mean ICU stay duration was 4.39 
days compare to sick euthyroid syndrome negative patients in whom mean ICU 
stay duration was 3.45 days with p value of 0.007** so this observation was 
statistically significant. 
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DIABETES AND SICK EUTHYROID SYNDROME 
DIABETES
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 DIABETES AND SICK EUTHYROID SYNDROME 
DIABETES SES+ve Percentage SES –ve Percentage TOTAL 
Present 6 60% 4 40% 10 
Absent 15 37.5% 25 62.5% 40 
 21  29  50 
 
In our study if the patient who had DIABETES, the occurrence of sick euthyroid 
syndrome was 60% and patients who presented with NO DIABETES, the 
occurrence of sick euthyroid syndrome was 37.5%. p value was 0.197 that 
statistically insignificant. 
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 HYPERTENSION AND SICK EUTHYROID SYNDROME 
HYPERTENSION
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HYPERTENSION AND SICK EUTHYROID SYNDROME 
HYPERTENSION SES +ve Percentage
SES –
ve Percentage TOTAL 
Present 11 58% 8 42% 19 
Absent 10 32% 21 68% 31 
 21  29  50 
 
In our study patients who had HYPERTENSION the occurrence of sick euthyroid 
syndrome was 58% and patients who presented with NO HYPERTENSION the 
occurrence of sick euthyroid syndrome was 32%. p value was 0.10 that statistically 
insignificant. 
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  SMOKING AND SICK EUTHYROID SYNDROME 
SMOKING
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SMOKING AND SICK EUTHYROID SYNDROME 
SMOKING SES+ve Percentage SES-ve Percentage TOTAL 
Present 11 41% 16 59% 27 
Absent 10 43% 13 57% 23 
 21  29  50 
 
In our study patient  who had SMOKING as a risk factor, the occurrence of sick 
euthyroid syndrome was 41% and patients with NO SMOKING the occurrence of 
sick euthyroid syndrome was 43%  .p value was 0.50 that statistically insignificant. 
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ALCOHOL INTAKE AND SICK EUTHYROID SYNDROME 
ALCOHOL
POSNEG
C
ou
nt
16
15
14
13
12
11
10
9
8
SICK EUTHYROID SYN
NEG
POS
9
12
14
15
 
ALCOHOL INTAKE AND SICK EUTHYROID SYNDROME 
ALCOHOL SES+ve Percentage SES-ve Percentage TOTAL 
Present 9 39% 14 61% 23 
Absent 12 44% 15 56% 27 
 21  29  50 
 
In our study patients who had ALCOHOL intake the occurrence of sick euthyroid 
syndrome was 39% and patients who presented with no H/O of  ALCOHOL intake 
the occurrence of sick euthyroid syndrome was 44%.  This observation was 
statistically insignificant with p value of 0.50 .  
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TOTAL CHOLESTEROL LEVEL AND SICK EUTHYROID SYNDROME 
TOTAL CHOL
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  TOTAL CHOLESTEROL LEVEL AND SICK EUTHYROID SYNDROME 
 SES +ve 
PERCENTAG
E 
SES-
ve 
PERCENTAG
E TOTAL 
<200 mg 10 53% 9 47% 19 
200 to 
239 mg 4 25% 12 75% 16 
>240 mg 7 47% 8 53% 15 
 21  29  50 
 
In our study patients who presented with  fasting cholesterol level <200 mg the 
occurrence of sick euthyroid syndrome was 53%, fasting cholesterol level 200 to 
239mg the occurrence of sick euthyroid syndrome was 25% and fasting cholesterol 
level >240mg the occurrence of sick euthyroid syndrome was 47%. This 
observation was statistically insignificant with P value of 0.50 .  
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 TRIGLYCERIDE LEVEL AND SICK EUTHYROID SYNDROME 
TRIGLYCERIDE mg/dl
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TRIGLYCERIDE LEVEL AND SICK EUTHYROID SYNDROME 
TRIGLYCERIDE SES+ve PERCENTAGE SES-ve PERCENTAGE TOTAL
<200 mg 17 46% 20 54% 37 
>200 mg 4 31% 9 69% 13 
 21  29  50 
 
In our study patients who presented with fasting TRIGLYCERIDE level <200 mg 
the occurrence of sick euthyroid syndrome was 46% and fasting TRIGLYCERIDE 
level >200mg the occurrence of sick euthyroid syndrome was 31%. This 
observation was statistically insignificant with P value of 0.50 .  
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HDL LEVEL AND SICK EUTHYROID SYNDROME 
HDL mg /dl
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 HDL LEVEL AND SICK EUTHYROID SYNDROME 
HDL SES +ve PERCENTAGE SES-ve PERCENTAGE TOTAL 
<40 mg 11 46% 13 54% 24 
>40 mg 10 38% 16 62% 26 
 21  29  50 
 
In our study patients who presented with fasting HDL level <40mg the occurrence 
of sick euthyroid syndrome was 46% and fasting HDL level >40mg the occurrence 
of sick euthyroid syndrome was 38%. This observation was statistically 
insignificant with P value of 0.50 .  
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 DEATH AND SICK EUTHYROID SYNDROME 
SICK EUTHYROID SYNDROME
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 SES +ve PERCENTAGE SES-ve PERCENTAGE  
MALE 2 100% - - 2 
FEMALE 1 100% - - 1 
 
In our study occurrence of sick euthyroid syndrome among death patients was 
100%. 
Mean T3 level in death patients was 0.3ng/ml 
Mean T4 level in death patients was 58ng/ml 
Mean TSH level in death patients was 0.77 micro unit/ml. 
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 THYROID HORMONE STATUS IN SICK EUTHYROID PATIENTS 
 
THYROID HORMONE STATUS IN SICK EUTHYROID PATIENTS 
 LOW T3 LOW           T3 and T4 
LOW 
T3,T4.TSH TOTAL 
SES+ve patients 15(71%) 5(24%) 1(5%) 21 
 
In our study, in  sick euthyroid syndrome patients most common presentation was 
LOW T3 (71%), second most common was LOW T3 & T4 (24%) and least 
common was LOW T3,T4,TSH (5%). 
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MEAN LEVELS OF HORMONES AND SICK EUTHYROID SYNDROME 
 SES +ve 
pts(n) 
Std 
deviation
SES-ve 
pts(n) 
Std 
deviation 
TOTAL Std 
deviation
p 
value 
T3mean 
(ng/ml) 
0.41(21) 0.0210 1.02(29) 0.3561 0.77(50) 0.40716 0.000** 
T4 mean 
(ng/ml) 
69(21) 23.2382 87(29) 17.4245 80(50) 21.81526 0.003** 
TSH mean 
(micro 
unit/ml) 
1.33(21) 0.8935 1.73(29) 1.0784 1.56(50) 1.01452 0.176** 
 
In our study, in sick euthyroid syndrome positive patients  
        Mean T3 level    -   0.41ng/ml, 
        Mean T4 level    -   69ng/ml, 
        Mean TSH level -   1.33micro unit /ml 
In our study, in sick euthyroid syndrome negative patients  
        Mean T3 level   -   1.02ng/ml, 
        Mean T4 level   -   87ng/ml, 
        Mean TSH level - 1.73micro unit /ml 
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MEAN LEVELS OF HORMONES AND SICK EUTHYROID SYNDROME  
 
 In our study, in sick euthyroid syndrome positive patients at Day 1 
        Mean T3 level    -   0.41ng/ml, 
        Mean T4 level    -   71ng/ml, 
        Mean TSH level -   1.43micro unit /ml 
In our study, in sick euthyroid positive patients repeat thyroid function test at Day7 
        Mean T3 level    -   0.68ng/ml, 
        Mean T4 level    -   84ng/ml, 
        Mean TSH level -   1.61micro unit /ml 
This observation was statistically significant with above p values. 
 
D1SES +ve 
pts(n) 
Std 
deviation 
D7SES +ve 
pts(n) 
Std 
deviation 
p value 
T3mean 
(ng/ml) 0.41(18) 0.0185 0.6839(18) .1312 <.001** 
T4 mean 
(ng/ml) 71(18) 23.4377 84.1111(18) 16.8484 <.001** 
TSH mean 
(micro 
unit/ml) 
1.43(18) 0.9233 1.6061(18) .8201 0.006** 
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DISCUSSION 
OCCURRENCE OF SICK EUTHYROID AMONG MI PATIENTS 
In our study 42% of acute ST elevation MI patients had sick euthyroid syndrome. 
So occurrence of sick euthyroid syndrome in our patients was 42%. p value was 
0.258.  So occurrence of sick euthyroid positivity rate was not statistically 
significant. This implies that occurrence of sick euthyroid positivity rate may vary. 
 In Eber B et al the occurrence of sick euthyroid syndrome in patients with acute 
myocardial infarction has been reported was 40 %. 1 
 In overall the occurrence of one or more abnormalities of thyroid function tests in 
patients with non thyroidal medical illnesses   like starvation, sepsis, surgery, 
myocardial infarction, CABG surgery, bone marrow transplantation, etc …has 
been reported from 40% to 70%. 
SEX DISTRIBUTION AND SICK EUTHYROID SYNDROME 
In our study occurrence of sick euthyroid syndrome was 60% among females and 
37.5% among males. This observation was statistically insignificant with the         
p value of 0.50. In previous studies also the occurrence of sick euthyroid syndrome 
in sex distribution was same. 
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AGE GROUP & SICK EUTHYROID SYNDROME 
In our study in the age group of 20 to 39, no one had sick euthyroid syndrome. In 
the age group of 40 to 59, 37% had sick euthyroid syndrome. In the age group of 
>60, 55% of patients had sick euthyroid syndrome. p value was 0.206 that 
statistically insignificant. So In our study age group does not influence the 
occurrence of sick euthyroid syndrome positivity. 
 
 TYPES OF MI AND SICK EUTHYROID SYNDROME  
In our study occurrence of sick euthyroid syndrome in AWMI patients was 36%, in 
IWMI patients was 42% and in others 100%. p value was 0.20 that statistically 
insignificant. So In our study type of MI does not influence the occurrence of sick 
euthyroid syndrome positivity. 
To the best of our knowledge no study compared the type of MI and sick euthyroid 
syndrome. 
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KILLIP CLASS AND SICK EUTHYROID SYNDROME 
In Killip T, Kimball JT et al2 study, KILLIP CLASS predicted the severity and 
mortality in acute coronary syndrome. In  Killip class I the mortality rate was 6%, 
Killip class II   was 17%, Killip class III  was  38% and Killip class IV was 81%.  
In our study patients who presented with KILLIP 1 the sick euthyroid syndrome 
occurrence was 25%, in KILLIP 2  was 59%, in KILLIP 3 was 67% and KILLIP 4  
was 100%.p value was 0.05* that statistically significant between the KILLIP 1 
and KILLIP 2. 
In our study KILLIP 2 patients had(higher mortality and morbidity) higher 
occurrence of sick euthyroid syndrome (59%) to KILLIP 1(25%) This observation 
was statistically significant with P value of .05*. 
In our study 47.6% of sick euthyroid  positive  patients are  in KILLIP 2 .But sick 
euthyroid  negative patients only 24.1% are in KILLIP 2.p value was 0.032** that 
statistically significant . In Killip T, Kimball JT et al2 study,higher the  KILLIP 
CLASS  higher the  severity and mortality in acute coronary syndrome reported. 
 In our study Sick euthyroid syndrome positivity patients have higher KILLIP class 
than negative patients. Considering this Sick euthyroid syndrome positivity status 
predicts the severity and mortality in acute myocardial infarction. 
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In our study Mean T3 level, Mean T4 level, Mean TSH level progressively 
decreased in patients who presented with increased severity as evidenced by 
KILLIP class. The decrease of Mean level of T3,T4 in various class of  KILLIP 
was statistically significant. The decrease of Mean level of TSH in various class of 
KILLIP was statistically insignificant. In Pavlou HN et al. Angiology 2002; 53: 
699-707. Study also observed that progressive decrease of Mean T3 level, Mean 
T4 level and Mean TSH level with increased severity of myocardial infarction in 
which severity was assessed by KILLIP class. In Friberg L et al Arch Intern Med 
2002; 162: 1388-1394.study observed that mortality was high among patients with 
the most pronounced thyroid level depression. Medha Rajappa and S.K. Sen et al3 
Study concluded that occurrence of sick euthyroid syndrome and the degree of T3 
decrease is proportional to the severity of cardiac damage and may have a possible 
prognostic value So analyzing various studies our study also predicts the severity 
by more suppression of thyroid hormone. 
 Thus, T3 blood levels may contribute to the elaboration of an AMI severity index. 
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EJECTION FRACTION AND SICK EUTHYROID SYNDROME 
In our study, patients presented with LVEF<50 the occurrence of sick euthyroid 
syndrome was 60% and patients who presented with LVEF>50 was 24%. In our 
study, patients who presented with LVEF<50 the sick euthyroid syndrome 
positivity was high compare to high LVEF >50. p value was0.01** that 
statistically significant. 
 In our study 71.4% of sick euthyroid positive patients are in LVEF<50 But 34.5% 
of sick euthyroid negative patients only in this group. p value was 0.010** that 
statistically significant. In   Hallstrom A et al7 . J Am Coll Cardiol. 1995 
May;25(6):1250-7.study concluded that low left ventricular ejection fraction are 
strongly associated with morbidity and mortality after acute myocardial infarction .  
Sick euthyroid positive patients are high likelihood to have LVEF<50. So the sick 
euthyroid syndrome positivity predicts the high mortality and morbidity than 
negative individuals in acute myocardial infarction. 
In our study ,patients who presented with LVEF<50 Mean T3 level ,Mean T4 
level, Mean TSH level were moderately low compared to  patients who presented 
with  LVEF>50. In our study patients who presented with the LVEF <50 and 
LVEF>50 the decrease of MeanT3level, Mean T4 level and Mean TSH level 
between these groups was statistically significant.  
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In  Medha Rajappa and S.K. Sen et al Biomedical Research 2005; 16 (1): 15-18 
study observed that extent of decrease of Mean T3 level ,Mean T4 level, Mean 
TSH level  was more significant in patients in group I (with LVEF < 50%), who 
have a worse prognosis than those in group II. 
 So analyzing various studies our study also observed when the severity was 
increased as evidenced by low LVEF more suppression of thyroid hormone level 
occurs. 
ICU STAY AND SICK EUTHYROID SYNDROME 
In our study in sick euthyroid positive patients mean ICU stay duration was 4.39 
days compare to sick euthyroid syndrome negative patients in whom mean ICU 
stay duration was 3.45 days with p value of 0.007** so this observation was 
statistically significant. This implies that sick euthyroid positive patients have high 
morbidity. 
RISK FACTORS AND SICK EUTHYROID SYNDROME 
In our study patients who had DIABETES the occurrence of sick euthyroid 
syndrome was 60% and patients who presented with NO DIABETES the 
occurrence of sick euthyroid syndrome was 37.5% .The p value was insignificant. 
So in our study the presence of DIABETES does not influence the occurrence of 
sick euthyroid syndrome. 
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In our study patients who had HYPERTENSION the occurrence of sick euthyroid 
syndrome was 58% and patients who presented with NO HYPERTENSION the 
occurrence of sick euthyroid syndrome was 32%. The p value was insignificant. So 
in our study the presence of HYPERTENSION does not influence the occurrence 
of sick euthyroid syndrome. 
In our study patients with risk factor SMOKING the occurrence of sick euthyroid 
syndrome was 41%, patients who presented with NO SMOKING the occurrence of 
sick euthyroid syndrome was 43%. The p value was insignificant. So in our study 
the presence of SMOKING habit does not influence the occurrence of sick 
euthyroid syndrome. 
In our study patients who had ALCOHOL intake the occurrence of sick euthyroid 
syndrome was 39%, patients who presented with no H/O of ALCOHOL intake the 
occurrence of sick euthyroid syndrome was 44%. The p value was insignificant. So 
in our study the H/O ALCOHOL intake does not influence the occurrence of sick 
euthyroid syndrome. 
 
To the best of our knowledge no study compared the risk factors and sick 
euthyroid syndrome. 
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TOTAL CHOLESTEROL LEVEL AND SICK EUTHYROID SYNDROME 
In our study patients who presented with  fasting cholesterol level <200 mg the 
occurrence of sick euthyroid syndrome was 53%, fasting cholesterol level 200 to 
239mg the occurrence of sick euthyroid syndrome was 25% and fasting cholesterol 
level >240mg the occurrence of sick euthyroid syndrome was 47%. p value was 
0.50 that statistically insignificant. So in our study cholesterol level does not 
influence the sick euthyroid positivity. 
TRIGLYCERIDE LEVEL AND SICK EUTHYROID SYNDROME 
In our study patients who presented with fasting TRIGLYCERIDE level <200 mg 
the occurrence of sick euthyroid syndrome was 46% and fasting TRIGLYCERIDE 
level >200mg the occurrence of sick euthyroid syndrome was 31%. p value was 
0.50 that statistically insignificant. So in our study TRIGLYCERIDE level does 
not influence the sick euthyroid positivity. 
HDL LEVEL AND SICK EUTHYROID SYNDROME  
In our study patients who presented with fasting HDL level <40mg the occurrence 
of sick euthyroid syndrome was 46% and fasting HDL level >40mg the occurrence 
of sick euthyroid syndrome was 38%. p value was 0.50 that statistically 
insignificant. So in our study HDL level does not influence the sick euthyroid 
positivity. 
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DEATH AND SICK EUTHYROID SYNDROME 
In our study occurrence of sick euthyroid syndrome among death patients was 
100%. 
Mean T3 level in death patients was 0.39ng/ml 
Mean T4 level in death patients was 58ng/ml 
Mean TSH level in death patients was 0.7micro unit/ml. 
MEAN LEVELS OF HORMONES AND SICK EUTHYROID SYNDROME 
In our study, sick euthyroid syndrome positive patients had 
        Mean T3 level    -   0.41ng/ml, 
        Mean T4 level    -   69ng/ml, 
        Mean TSH level -   1.33micro unit /ml 
and sick euthyroid syndrome negative patients had 
        Mean T3 level   -   1.02ng/ml, 
        Mean T4 level   -   87ng/ml, 
        Mean TSH level - 1.73micro unit /ml. 
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On comparison between the groups of sick euthyroid positive and negative 
patients, the decrease of Mean T3,Mean T4 level in sick euthyroid positive patients 
was statistically significant as evidenced by p value. But the decrease of Mean 
TSH level in sick euthyroid positive patients was statistically insignificant. 
In our study, in sick euthyroid syndrome positive patients repeat thyroid function 
test done at Day 7, the Mean T3 level  was  0.68ng/ml, Mean T4 level  was   
84ng/ml and Mean TSH level was  1.61micro unit /ml. 
This observation was statistically significant when we compare to Mean T3,Mean 
T4 and Mean TSH was done at Day 1.This observation confirms the occurrence of  
sick euthyroid syndrome and  indicates it was transient manifestation.  
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LIMITATIONS OF THE STUDY  
1. Thyroid function test done only at I st day and 7 th day. 
2. Free T3, free T4, Reverse t3 is not measured in our study 
3. Secondary hypothyroidism could not be excluded in our study patients. 
4. Our study was a small study done with 50 patients only. 
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CONCLUSION 
Occurrence of sick euthyroid syndrome was common in acute ST elevation 
myocardial infarction patients. 
Our study shows that of 42% acute ST elevation myocardial infarction patients had 
sick euthyroid syndrome positivity. 
The commonest abnormalities is found to be a low level of total T3 as 
demonstrated in our study where 71% of the patients had low level total T3. 
The next most common abnormalities is found to be both low level of total T3 
&total T4(24%) 
As the severity of the illness increases sick euthyroid syndrome positivity rate was 
increased.  (KILLIP 1  sick euthyroid syndrome positivity was 25%, in KILLIP 2 
patients  positivity was 59%, in KILLIP 3 patients was 67% and KILLIP 4 patient 
was 100%. patients presented with LVEF<50 the positivity of sick euthyroid 
syndrome was 60% and patients presented with  LVEF>50 was 24%) 
The degree of T3 decrease is proportional to the severity of cardiac damage and 
may have a possible prognostic value.  (LVEF<50 Mean T3 level 0.62 ng/ml, 
LVEF>50 Mean T3 level 0.9ng/ml) 
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The changes in the thyroid hormone status return to normal once the patient 
recovers from the critical illness. 
Though these patients have abnormalities in the thyroid hormone status they are 
clinically euthyroid. 
Thyroid hormone system is rapidly down regulated in acute myocardial infarction. 
This may be beneficial during acute ischemia. 
 The sick euthyroid syndrome positivity rate is proportional to the severity of 
cardiac damage (as evidenced by KILLIP class and Ejection fraction)  and may 
have a possible prognostic value. Thus sick euthyroid syndrome positivity may 
contribute to the elaboration of an AMI severity index. 
The role of thyroid hormone replacement as a method of treatment of sick 
euthyroid syndrome is still controversial and there are no proper studies to 
recommend this. 
Treatment of underlying condition is the treatment of choice. 
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AREAS OF FUTURE RESEARCH 
1.Thyroid function tests including total T3,free T3,reverse T3,total T4,free T4 and 
TSH may be done on    day 1, day4,day7and 30th day  and severity  can be  
correlated with APACHE score and thyroid hormone levels. 
2. Thyroid function tests including total T3, free T3, reverse T3, total T4, free T4 
and TSH may be done on unstable angina and congestive cardiac failure patients. 
3. To study the effect of thyroid hormone supplementation and to improve the 
prognosis of acute ST elevation myocardial infarction patients with Sick euthyroid 
syndrome positivity. 
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RECOMMENDATIONS 
1.The presence of Sick euthyroid syndrome in acute ST elevation myocardial 
infarction patients may contribute to the elaboration of an AMI severity index.  
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      SUMMARY 
Euthyroid sick syndrome can be described as abnormal findings on thyroid 
function tests that occur in the setting of a non thyroidal illness (NTI) without 
preexisting hypothalamic-pituitary and thyroid gland dysfunction.  
A decreased level of serum total triiodothyronine (T3) is the most common thyroid 
function abnormality in patients with acute illness[14] and can be detected within 2 
hours after the onset of severe physical stress.[25] As the severity of illness 
progresses  thyroxine (T4).[26,27] also decreased. 
Acute myocardial infarction (AMI) is one of the most common critical illness in 
hospitalized patients. 
 Various studies in western world showed the occurrence of sick euthyroid 
syndrome in acute ST elevation myocardial infarction patients and such changes 
had a prognostic significance in determining severity the of AMI.  
The aim of the present investigation was to confirm  the  occurrence of sick 
euthyroid syndrome in acute ST elevation myocardial infarction in our  patients 
and to evaluate whether such changes have a prognostic significance in 
determining  the severity of AMI. 
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This study was conducted in the coronary care unit, GGH, Chennai in 
collaboration with institute of internal medicine, institute of biochemistry and 
institute of Cardiology. It was a prospective study done during the period from Jan 
2009 –Oct 2009 .50 patients with history, clinical features suggestive of ST 
elevation myocardial infarction were selected irrespective of age and sex. 
Patients with clinical parameters and ECG suggestive of ST elevation myocardial 
infarction were taken into consideration. Each patient registered for the study went 
through detailed clinical evaluation as per the proforma. The severity was assessed 
by KILLIP classification criteria and ejection fraction. The serum of patients was 
analyzed for thyroid function tests at day 1 (T3,T4,TSH)and in sick euthyroid  
positive patients repeat  thyroid function tests done at day 7 to determine the  
reversal  of hormone status. 
In our study KILLIP 2 patients (higher mortality and morbidity )had higher  
positivity  of sick euthyroid syndrome (59%) than KILLIP 1(25%) and in patients 
who presented with LVEF<50 the  sick euthyroid syndrome positivity  was higher 
compare to high LVEF >50. Mean T3 level, Mean T4 level, Mean TSH level 
progressively decreased in patients presented with increased severity as evidenced 
by KILLIP class and ejection fraction and these values are statistically significant. 
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So compare to previous studies our study also proved that occurrence of sick 
euthyroid syndrome positivity and such positivity and level of progressive decrease 
of thyroid hormones predicts the severity of cardiac damage in our acute ST 
elevation myocardial infarction patients. 
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